Lexeo Therapeutics, Inc. (LXEO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on August 14, 2025, by Lexeo Therapeutics, Inc., a Delaware corporation. The filing primarily addresses executive leadership changes and references the release of financial results for the three and six months ended June 30, 2025.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing business highlights and financial results for the periods ended June 30, 2025. However, this specific 8-K text does not provide numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the referenced press release for specific financial data.
Material Changes and Executive Transitions
The most significant event reported is the transition of the Chief Financial Officer (CFO):
- Resignation: Dr. Kyle Rasbach resigned as CFO effective August 15, 2025. The resignation is not due to any disagreement with the Company.
- Appointment: Louis Tamayo was appointed CFO, Principal Financial Officer, and Principal Accounting Officer effective August 15, 2025.
- Transition: Dr. Rasbach will serve as an advisor through August 29, 2025, to assist with the transition.
Compensation Arrangements and Severance
New CFO (Louis Tamayo):
- Base Salary: $480,000 annually.
- Bonus: Discretionary target of 40% of base salary.
- Equity: 45,000 Restricted Stock Units (RSUs) and options to purchase 280,000 shares.
- Severance: Upon termination without cause or resignation for good reason (outside change in control), Mr. Tamayo is entitled to 12 months of base salary and COBRA coverage. In a change in control scenario, benefits include 12 months of base salary, 100% of the target bonus, COBRA coverage, and acceleration of unvested equity.
Outgoing CFO (Dr. Kyle Rasbach):
- Separation Payment: Lump sum of $128,000.
- Equity: Accelerated vesting of 40,466 unvested options.
Outlook, Risks, and Contingencies
The filing does not contain specific forward-looking guidance, risk factors, or unusual items beyond the standard disclosures regarding the executive transition. The Company notes that the information in the referenced press release is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the specific financial results (revenue, cash burn, net loss) for the three and six months ended June 30, 2025, by reviewing the press release attached as Exhibit 99.1.
- Confirm the effective date of the CFO transition (August 15, 2025) and the duration of the transition support period (through August 29, 2025).
- Review the total equity grant size for the new CFO (45,000 RSUs and 280,000 options) to assess potential dilution.
- Note the immediate cash outflow of $128,000 for the outgoing CFO's separation package.